CeriBell (NASDAQ:CBLL) VP David Foehr Sells 569 Shares

February 26, 2026 by InsiderTrades.com

Key Points

CEO sale: CEO Xingjuan Chao sold 2,084 shares at an average price of $19.79 for $41,242.36, trimming her stake to 725,164 shares (a 0.29% reduction) after several larger insider sales earlier this season.
Q4 beat and guidance: CeriBell reported Q4 EPS of ($0.36) vs. ($0.43) expected and revenue of $24.78M vs. $23.95M expected, and guided FY‑2026 revenue to roughly $111M–$115M, close to consensus.
Market view: the stock has a market cap of about $706M and a consensus analyst rating of "Moderate Buy" with an average price target of $24.67 (1‑yr range $10.01–$25.37).

CeriBell, Inc. (NASDAQ:CBLL - Get Free Report) VP David Foehr sold 569 shares of the stock in a transaction on Monday, February 23rd. The shares were sold at an average price of $19.79, for a total value of $11,260.51. Following the transaction, the vice president directly owned 18,331 shares in the company, valued at $362,770.49. The trade was a 3.01% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

David Foehr also recently made the following trade(s):

On Tuesday, February 24th, David Foehr sold 781 shares of CeriBell stock. The stock was sold at an average price of $19.98, for a total value of $15,604.38.
On Tuesday, February 3rd, David Foehr sold 5,556 shares of CeriBell stock. The shares were sold at an average price of $20.00, for a total value of $111,120.00.
On Monday, January 5th, David Foehr sold 5,556 shares of CeriBell stock. The stock was sold at an average price of $22.60, for a total value of $125,565.60.
On Wednesday, December 3rd, David Foehr sold 5,265 shares of CeriBell stock. The stock was sold at an average price of $16.83, for a total transaction of $88,609.95.

CeriBell Stock Performance

Shares of CBLL traded down $0.09 on Thursday, reaching $18.86. The company's stock had a trading volume of 143,858 shares, compared to its average volume of 345,803. The company has a debt-to-equity ratio of 0.12, a current ratio of 12.65 and a quick ratio of 12.25. CeriBell, Inc. has a 12-month low of $10.01 and a 12-month high of $25.37. The stock has a market capitalization of $699.71 million, a P/E ratio of -12.83 and a beta of 1.03. The stock's 50 day simple moving average is $21.20 and its two-hundred day simple moving average is $16.19.

CeriBell (NASDAQ:CBLL - Get Free Report) last issued its quarterly earnings results on Tuesday, February 24th. The company reported ($0.36) earnings per share for the quarter, topping the consensus estimate of ($0.43) by $0.07. The business had revenue of $24.78 million for the quarter, compared to analysts' expectations of $23.95 million. CeriBell had a negative net margin of 59.97% and a negative return on equity of 30.99%. Research analysts forecast that CeriBell, Inc. will post -2.46 earnings per share for the current fiscal year.

Analysts Set New Price Targets

CBLL has been the topic of a number of analyst reports. BTIG Research reaffirmed a "buy" rating and set a $30.00 price objective on shares of CeriBell in a research report on Wednesday, January 28th. Canaccord Genuity Group upped their price target on shares of CeriBell from $29.00 to $30.00 and gave the stock a "buy" rating in a research report on Wednesday, December 17th. JPMorgan Chase & Co. decreased their price objective on shares of CeriBell from $21.00 to $17.00 and set an "overweight" rating on the stock in a research report on Wednesday, November 5th. Finally, TD Cowen reiterated a "buy" rating on shares of CeriBell in a research note on Tuesday, December 9th. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $24.67.

Check Out Our Latest Stock Analysis on CBLL

Key Headlines Impacting CeriBell

Here are the key news stories impacting CeriBell this week:

Positive Sentiment: Q4 beat on EPS and revenue — CeriBell reported Q4 EPS of ($0.36) vs. a consensus of ($0.43) and revenue of $24.78M vs. $23.95M expected, a beat that supports the recent uptick in the share price. MarketBeat: Q4 Results & Conference Call
Positive Sentiment: FY‑2026 revenue guidance provided — Management gave revenue guidance of roughly $111M–$115M for FY‑2026, which is close to consensus (~$112.7M), offering a clearer growth target for the year. Business Insider: Full Year Results & Guidance
Positive Sentiment: Earnings call highlighted revenue surge and market expansion — Management commentary and the call transcript emphasized accelerating revenue and expansion into new markets, supporting upside potential if execution continues. Yahoo Finance: Q4 2025 Earnings Call Highlights
Neutral Sentiment: Short‑interest data appears unreliable this cycle — the published short‑interest entry shows zero shares / NaN change, which is likely a reporting artifact and provides no actionable signal today.
Negative Sentiment: Multiple insider sales disclosed — several senior executives (CEO Xingjuan Chao, CFO Scott Blumberg, CTO Raymond Woo, CRO Joseph Manni and a VP) sold small amounts of stock at roughly $19.79–$19.98, reducing their positions by fractions of a percent; while sizes are modest relative to total holdings, clustered insider selling can create short‑term investor concern. InsiderTrades: Xingjuan Chao Sale SEC Filing: CEO Ownership

Hedge Funds Weigh In On CeriBell

A number of hedge funds and other institutional investors have recently modified their holdings of CBLL. Bank of New York Mellon Corp grew its stake in CeriBell by 1,945.9% during the fourth quarter. Bank of New York Mellon Corp now owns 1,221,927 shares of the company's stock valued at $26,797,000 after acquiring an additional 1,162,200 shares in the last quarter. KCM Capital Inc bought a new position in shares of CeriBell during the 4th quarter valued at about $21,930,000. Royce & Associates LP purchased a new position in shares of CeriBell during the fourth quarter valued at about $11,695,000. Adage Capital Partners GP L.L.C. bought a new stake in shares of CeriBell in the fourth quarter worth about $10,965,000. Finally, CenterBook Partners LP boosted its stake in CeriBell by 448.0% during the third quarter. CenterBook Partners LP now owns 476,554 shares of the company's stock valued at $5,476,000 after buying an additional 389,584 shares during the last quarter.

About CeriBell

(Get Free Report)

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell's solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company's product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.